Voyager Therapeutics, Inc. (VYGR) Now Covered by Analysts at Raymond James Financial, Inc.
Investment analysts at Raymond James Financial, Inc. assumed coverage on shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) in a report issued on Thursday. The firm set an “outperform” rating and a $35.00 price target on the stock. Raymond James Financial, Inc.’s target price suggests a potential upside of 45.83% from the company’s previous close.
Other equities research analysts also recently issued research reports about the company. Evercore ISI began coverage on Voyager Therapeutics in a report on Wednesday, August 16th. They set an “outperform” rating and a $12.00 target price for the company. BidaskClub raised Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, July 13th. ValuEngine downgraded Voyager Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, July 28th. Zacks Investment Research downgraded Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Voyager Therapeutics in a report on Tuesday, August 8th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $26.29.
Voyager Therapeutics (NASDAQ VYGR) traded up 7.04% during trading on Thursday, reaching $25.69. 348,961 shares of the company’s stock traded hands. The firm’s market cap is $691.14 million. The company has a 50 day moving average of $15.89 and a 200 day moving average of $11.35. Voyager Therapeutics has a one year low of $8.10 and a one year high of $25.74.
Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, August 8th. The company reported ($0.73) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.11). Voyager Therapeutics had a negative return on equity of 46.15% and a negative net margin of 712.22%. The firm had revenue of $1.18 million for the quarter, compared to analyst estimates of $3.27 million. Equities research analysts predict that Voyager Therapeutics will post ($2.84) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Voyager Therapeutics, Inc. (VYGR) Now Covered by Analysts at Raymond James Financial, Inc.” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/10/12/voyager-therapeutics-inc-vygr-now-covered-by-analysts-at-raymond-james-financial-inc.html.
In other news, insider Bernard Ravina sold 5,490 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $10.00, for a total transaction of $54,900.00. Following the completion of the transaction, the insider now directly owns 17,157 shares of the company’s stock, valued at approximately $171,570. The sale was disclosed in a filing with the SEC, which is available at this link. Over the last ninety days, insiders have sold 27,450 shares of company stock valued at $321,769. Corporate insiders own 8.00% of the company’s stock.
Several hedge funds have recently made changes to their positions in VYGR. Teachers Advisors LLC raised its stake in shares of Voyager Therapeutics by 9.8% during the 4th quarter. Teachers Advisors LLC now owns 20,604 shares of the company’s stock worth $262,000 after buying an additional 1,847 shares during the period. Wells Fargo & Company MN raised its stake in shares of Voyager Therapeutics by 114.4% during the 1st quarter. Wells Fargo & Company MN now owns 83,577 shares of the company’s stock worth $1,107,000 after buying an additional 44,599 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Voyager Therapeutics by 15.6% during the 1st quarter. Bank of New York Mellon Corp now owns 44,018 shares of the company’s stock worth $582,000 after buying an additional 5,952 shares during the period. Wellington Management Group LLP raised its stake in shares of Voyager Therapeutics by 17.4% during the 1st quarter. Wellington Management Group LLP now owns 131,312 shares of the company’s stock worth $1,739,000 after buying an additional 19,450 shares during the period. Finally, Schwab Charles Investment Management Inc. raised its stake in shares of Voyager Therapeutics by 3.7% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 28,921 shares of the company’s stock worth $383,000 after buying an additional 1,026 shares during the period. 40.70% of the stock is owned by institutional investors and hedge funds.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.